ライフサイエンスコーパス: hyperimmune

1 h high viremia, suggesting a direct role for hyperimmune activation and an indirect role for viremia

2 , chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persis

3 on of acutely SHIV-infected macaques induced hyperimmune activation and remarkable expansion of CD4+

4 type 1 (HIV-1) infection is associated with hyperimmune activation and systemic depletion of CD4(+)

5 e of chimpanzees to SIVcpz infection-induced hyperimmune activation could be the result of the expres

6 nation antiretroviral therapy by suppressing hyperimmune activation in HIV-infected individuals.

7 Hyperimmune activation is a strong predictor of disease

8 nic SIV/HIV infections is marked by systemic hyperimmune activation, immune dysregulation, and profou

9 li strain SP16 (ATCC 49776) genomic DNA with hyperimmune and convalescent swine sera.

10 the native virus capsid and reacted with pig hyperimmune and convalescent-phase sera to PEC Cowden in

11 a coli cells, immunoblotted, and probed with hyperimmune and/or convalescent-phase antiserum to rapid

12 n guinea pigs were used to study the role of hyperimmune anti-glycoprotein B (gB) serum in modificati

13 Hyperimmune anti-HIV immunoglobulin (HIVIG) is derived f

14 The pharmacokinetics and safety of hyperimmune anti-human immunodeficiency virus (HIV) intr

15 n antigen-detection ELISA was developed with hyperimmune antibodies raised to human group C rotavirus

16 production, high sensitivity to MmmSC rabbit hyperimmune antisera in vitro, and unique polymorphisms

17 ow the greatest sequence homology, we tested hyperimmune antisera prepared for each virus against bac

18 d SV capsid proteins were demonstrated using hyperimmune antisera raised in animals and sera collecte

19 n enzyme-linked immunosorbent assay based on hyperimmune antisera to recombinant SeV was highly speci

20 ed to identify epitopes recognized by rabbit hyperimmune antisera to Rickettsia prowazekii SPA.

21 an ex vivo borreliacidal assay to show that hyperimmune antiserum against DbpA, but not OspA, killed

22 with CT, and a reduced immunoreactivity with hyperimmune antiserum.

23 were randomly assigned (1:1:1) to take oral hyperimmune bIgG raised against CFA/I minor pilin subuni

24 ve to the prophylactic use of antibiotics, a hyperimmune bovine milk antibody product with specific a

25 es and other novel biological agents such as hyperimmune caprine serum are being developed based on n

26 Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated coliti

27 mmune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and a

28 Hyperimmune DbpA antiserum killed a large number of B. b

29 gs were completely protected by injection of hyperimmune equine IgG when treatment was initiated earl

30 he neutralizing component of cytomegalovirus hyperimmune globulin (CMV-HIG), we performed serial depl

31 s followed by low-dose cytomegalovirus (CMV) hyperimmune globulin (CMV-Ig) combined with quadruple im

32 s that a combination of ganciclovir plus CMV hyperimmune globulin (CMVIG) is more effective than ganc

33 Anti-cytomegalovirus (anti-CMV) hyperimmune globulin (HIG) has demonstrated efficacy in

34 ized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immuniz

35 ared aggressive CMV prophylaxis (n = 21, CMV hyperimmune globulin [CMVIG] plus four weeks of intraven

36 s reactive with gM/gN from pooled human HCMV hyperimmune globulin by affinity purification using reco

37 women who could be evaluated, treatment with hyperimmune globulin did not significantly modify the co

38 % (18 fetuses or infants of 61 women) in the hyperimmune globulin group and 44% (27 fetuses or infant

39 obstetrical adverse events was higher in the hyperimmune globulin group than in the placebo group (13

40 unity as achieved in the passive transfer of hyperimmune globulin has had a tremendous impact on publ

41 We evaluated the efficacy of hyperimmune globulin in a phase 2, randomized, placebo-c

42 lactic vaccine or for producing C. difficile hyperimmune globulin is justified.

43 r the presumed onset of infection to receive hyperimmune globulin or placebo every 4 weeks until 36 w

44 Immunoprophylaxis with hyperimmune globulin or with a humanized monoclonal anti

45 shed in 2005, administration of CMV-specific hyperimmune globulin to pregnant women with primary CMV

46 ntreated congenital infection, HCMV-specific hyperimmune globulin treatment, and uninfected controls.

47 With hyperimmune globulin treatment, placentas appeared uninf

48 76% of neutralizing activities in HCMV human hyperimmune globulin, consistent with earlier reports th

49 maximum of six treatments, plus intravenous hyperimmune globulin, tacrolimus, mycophenolate mofetil,

50 uality attributes comparable to those of CMV hyperimmune globulin.

51 high-risk (D+/R-) for CMV also received CMV hyperimmune globulin.

52 oNT/A, a potency 90 times greater than human hyperimmune globulin.

53 m patients with active coccidioidomycosis, a hyperimmune goat anti-Ag2 serum, and a murine anti-Ag2 m

54 genes of bovine rotavirus strain UK, and two hyperimmune guinea pig antisera to each reassortant, and

55 These findings could explain the efficacy of hyperimmune IgG for treatment of primary CMV infection d

56 ined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administere

57 of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 H

58 nistration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit fo

59 ) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were char

60 py using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reporte

61 thy volunteers for the purpose of developing hyperimmune intravenous immunoglobulin.

62 Hyperimmune, late xenograft rejection, and naive sera we

63 -specific affinity-purified IgG from malaria hyperimmune Liberian adults, was assessed by the opsonic

64 N40 and 9 B. afzelii PKo isolates from OspC hyperimmune mice or among 10 B. burgdorferi s.s. N40 and

65 N40 and 10 B. afzelii PKo isolates from DbpA hyperimmune mice, compared with input inocula.

66 library by probing with anti-E. chaffeensis hyperimmune mouse ascitic fluid.

67 V) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of h

68 ree ORFs, only M83 is strongly recognized by hyperimmune mouse serum.

69 ed infusions of immunoglobulins, either with hyperimmune or standard preparations, may help to reduce

70 at is dependent on monocytic cells, but this hyperimmune phenotype and its protective effects are los

71 ns were observed by CCIF between TGEV Miller hyperimmune pig antisera and all PEDV strains.

72 reatment of serious influenza is infusion of hyperimmune plasma.

73 n (CT), and enhanced immunoreactivity with a hyperimmune polyclonal antiserum generated against whole

74 hamsters that were passively immunized with hyperimmune rabbit anti-rAceES-2 serum exhibited more ra

75 A hyperimmune rabbit antiserum to an E2 hypervariable regi

76 er previous intravenous exposure of mice and hyperimmune rabbit serum did not neutralize the activity

77 brane proteins as determined by probing with hyperimmune rabbit serum.

78 feri B31 genomic library with cross-adsorbed hyperimmune rabbit serum.

79 broadest antibody response was obtained for hyperimmune rabbits with WR, which is pathogenic in rabb

80 erate potential antagonists of these serious hyperimmune reactions, we engineered soluble TCR mutants

81 ring B lymphocytes typical of a Th2-mediated hyperimmune response.

82 e therapeutically useful for attenuating the hyperimmune responses in a number of disorders.

83 bitory subunit (Galphai2) induces Th1-skewed hyperimmune responses in the colon, leading to chronic c

84 provide important clues regarding GC-related hyperimmune responses in the context of disease progress

85 1 is a potential therapeutic target to block hyperimmune responses induced by gram-negative bacteria.

86 odel have implications for understanding the hyperimmune responses that characterize some human disea

87 rise to adults with fewer Wigglesworthia and hyperimmune responses.

88 counting for the observed colonic Th1-skewed hyperimmune responses.

89 Injection of the hyperimmune sera (IgG) into normoglycemic nude mice bear

90 Hyperimmune sera from 40 of 47 patients showed an anti-a

91 Mouse hyperimmune sera generated against TBE serocomplex virus

92 The hyperimmune sera induced by the combined conjugates exhi

93 hibition and neutralization assays that used hyperimmune sera obtained from caesarian-derived, colost

94 ated neutralization titers exceeding that of hyperimmune sera of rabbits immunized with PA in Freund'

95 Passive transfer of either P. y. yoelii hyperimmune sera or anti-GST-PYC2 sera directed to the m

96 and simultaneous transfer of tumor cells and hyperimmune sera protected naive animals against tumor g

97 was completely inhibited by the addition of hyperimmune sera raised to the major fimbriae.

98 etions on both termini with bovine anti-PlpE hyperimmune sera showed that the immunodominant region i

99 were high, similar to those of pooled human hyperimmune sera.

100 Infusion of Lewis rat-specific hyperimmune serum (0.2 ml) resulted in HAR of Lewis rat

101 The majority of animals receiving hyperimmune serum after virus exposure and during early

102 We examined the effect of hyperimmune serum and primed T cells on the survival of

103 Hyperimmune serum and sensitized splenocytes were prepar

104 Both hyperimmune serum and the mAb reacted with intact human

105 stablished islet xenografts are resistant to hyperimmune serum as a result of a lack of target endoth

106 heart grafts were rejected after transfer of hyperimmune serum but not late xenograft rejection serum

107 Transfer of hyperimmune serum containing anti-C6VL TCR Abs into na i

108 well as by immunoblot analysis with a rabbit hyperimmune serum directed against a gH synthetic peptid

109 Hyperimmune serum from vaccinated mice reacted specifica

110 In contrast, SIV hyperimmune serum given subcutaneously prior to oral SIV

111 All animals administered hyperimmune serum homologous to the challenge virus befo

112 Reports of the use of hyperimmune serum in human influenza infection are spora

113 successful intervention by administration of hyperimmune serum may be narrow.

114 Performed before infection, transfer of hyperimmune serum prolonged survival of C3aR(-/-) mice.

115 Because passive transfer of hyperimmune serum protected mice from HSV-1 infection, w

116 of HCV in vitro was attempted with a rabbit hyperimmune serum raised against a homologous synthetic

117 Similarly, mice passively immunized with hyperimmune serum showed an inhibited B-cell response up

118 orcine islets removed from mice treated with hyperimmune serum showed no staining for IgG.

119 - and postexposure passive immunization with hyperimmune serum to prevent oral simian immunodeficienc

120 mouse serum, we investigated the ability of hyperimmune serum to recombinant Osp C (N40) to protect

121 Although use of hyperimmune serum to treat patients with severe influenz

122 protection was not completely restored after hyperimmune serum transfer.

123 Hyperimmune serum was administered 24 hrs before virus e

124 When this SIV hyperimmune serum was given to 3 newborns 3 weeks after

125 e toxins or toxoids) or passively immunized (hyperimmune serum) against combinations of superantigens

126 ice treated with normal human serum (NHS) or hyperimmune serum, or into presensitized GT-Ko mice.

127 ci than did those from recipients of anti-gB hyperimmune serum.

128 arental viruses when tested against parental hyperimmune serum.

129 from immune-mediated destruction in clinical hyperimmune syndromes.